STORM in the News
DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments from the conference and scientific findings the company presented at the meeting.
Read more
David Hardick, Director, Medicinal Chemistry spoke with Andy Extance, Royal Society of Chemistry on chemistry's role in cancer therapy and talks about how through screening, STORM identified first-in-class inhibitors of METTL3, effective against AML. STORM has now selected its first-in-class drug candidate, STC-15 for development towards first in human clinical studies in 2022.
Read more
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML
Read more
STORM Therapeutics’ METTL3 RNA Modifying Enzyme Inhibitor has been featured in DrugHunter’s April edition of Small Molecules of the Month.
Read more
See the BioNewsRound Award 2020 nomination submission
Read more